en · de · es · fr · pt
semax-notes.peptides6908.com › News › Semax Background And Molecular Structure — Explained

Semax Background And Molecular Structure — Explained

By Editorial Desk · published 2026-03-16 · last reviewed 2026-04-23 · News

intranasal route is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-04-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Semax Background and Molecular Structure

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.

Semax Background and Chemistry

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Semax at a glance

PropertyValueNotes
Molecular weight~813.9 Da (free heptapeptide)N-acetylated form is about 42 Da heavier
Residue count7 (heptapeptide)Four residues from ACTH(4-10), three added
AppearanceWhite to off-white powderUsually supplied lyophilized
Solubility classFreely soluble in waterAlso dissolves in DMSO and polar organic solvents
Related parent fragmentACTH(4-10)Parent motif is Met-Glu-His-Phe

Semax Origin and Molecular Structure

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Related pages on this site

Semax Peptide Background and Identity

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Semax Structure and Research Background

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Notes from published material

== System components == A typical laboratory FPLC consist of one or two high-precision pumps, a control unit, a column, a detection system and a fraction collector. Although it is possible to operate the system manually, the components are normally linked to a personal computer or, in older units, a microcontroller.

=== Conformational change in non-inhibitory functions === Certain non-inhibitory serpins also use the serpin conformational change as part of their function. For example, the native (S) form of thyroxine-binding globulin has high affinity for thyroxine, whereas the cleaved (R) form has low affinity. Similarly, transcortin has higher affinity for cortisol when in its native (S) state, than its cleaved (R) state. Thus, in these serpins, RCL cleavage and the S to R transition has been commandeered to allow for ligand release, rather than protease inhibition. In some serpins, the S to R transition can activate cell signalling events. In these cases, a serpin that has formed a complex with its target protease, is then recognised by a receptor. The binding event then leads to downstream signalling by the receptor. The S to R transition is therefore used to alert cells to the presence of protease activity. This differs from the usual mechanism whereby serpins affect signalling simply by inhibiting proteases involved in a signalling cascade.

The technology has wide application, in environmental testing laboratories, life science and food companies, chemical/petrochemical firms, power generation facilities, electronics manufacturers, government agencies, and academic institutions. For example, during semiconductor production, Dionex instruments are used to detect and prevent ionic contamination, which can cause degradation of semiconductor surfaces and deterioration of their electrical properties. The Environmental Protection Agency has approved instruments such as the Dionex AS4 column for the analysis of anions in drinking water. Dionex columns are used by municipalities seeking to ensure the safety of drinking water and by companies selling bottled waters. The company made a point of developing worldwide distribution channels: as of 2007 Dionex's sales were distributed relatively evenly between North America, Europe, and the Asia/Pacific area. In the area of ion chromatography (IC), Dionex controlled more than 70 percent of a $200 million worldwide market. In the newer area of high-performance liquid chromatography (HPLC), which Dionex entered in 1998, the company held a much smaller place (1%) in a much larger market ($2 billion market). Bowman directed the company from its early stages of development, as a small branch of a larger company with approximately $1 million in revenues in a year, to its position as publicly traded enterprise with an established international revenue stream in the hundreds of millions of dollars. Bowman retired as president and chief executive officer of Dionex in 2002.

== Gel Preparation Methods == The process of gel formation involves finding a balance between the concentrations of the gelator and the solvent. When adding a gelator to the solvent, the mixture remains in liquid state. As the concentration of the gelator increases to a certain critical concentration (gelling point), gelation occurs through swelling to form the semi-solid gel. Further increasing the concentration of the gelator beyond the gelling point will increase gel viscosity. The exact gelling point varies depending on the properties of the gelator and the solvent, such as structure uniformity, molecular weight of the polymer, and flexibility of the polymer chain. Generally, gels are prepared by firstly dissolving the soluble excipients in the solvent. The solution is then mixed using a mechanical stirrer. After that, the gelator is added slowly to the stirred mixture in order to avoid aggregation. Then, the mixture is continuously stirred until the polymer dissolves and a gel gradually forms. The gel is allowed to settle for one to two days before the final consistency of the gel can be reached. The exact method of preparing gels depends on the properties of the formulation ingredients.

== History == Alec D. Bangham discovered liposomes in the 1960s as spherical vesicles made of a phospholipid bilayer that houses hydrophilic cores. The liposomes were then studied to uncover the properties of biological membranes and a hydration method was discovered to prepare artificial liposomes from 1968 to 1975. Since then, multiple methods of preparing liposomes have been utilized and their characteristics (physical and chemical) have been studied. Monoclonal antibodies are proteins that stick to specific antigens that tag specific cells and can be synthesized in the lab. They were first generated in 1975 and have since advanced to being used for immunotherapy. Immunolipsomes were developed utilizing both of these components. The first anticancer drug made with this method was doxorubicin (DOX) in the 1990s.

Sources: en.wikipedia.org

Background from the literature

However, by careful optimization of instrument parameters which cause ion heating, hydrogen scrambling can be minimized to a degree which preserves the solution phase isotopic labeling until fragmentation can be performed using a technique where scrambling does not occur. More recently, ultraviolet photodissociation (UVPD) has also been investigated as a possible fragmentation technique to localize deuterium within peptides and proteins. In this regard, the conclusions have been mixed, while it is possible to obtain UVPD fragments which has not undergone scrambling under certain conditions, others have shown that scrambling can occur for both peptides and proteins during the UVPD fragmentation step itself. The theory consolidating these apparent contradictions has to do with the dual fragmentation pathway that may arise from UV irradiation of peptides and proteins, i.e. direct and statistical dissociation. That is, if experimental conditions favor direct dissociation and the precursor ion is kept at low internal energies before and during fragmentation the deuterium level of the resulting fragments will correspond to the non-scrambled precursor. However, experimental conditions may favor statistical dissociation during UV irradiation, especially at long irradiation times and low gas pressure, leading to internal conversion of the electronic excitation energy contributed by the UV photons. The result is vibrational excitation of the irradiated molecule which in turn undergo scrambling.

A bar, also called a snack bar or a food bar, is a food made of processed ingredients formed into the shape of a bar. Bars typically have a long shelf life and contain high energy ingredients. There are several popular types of bar, including candy bars, protein bars, energy bars, granola bars and fruit bars. They are one of the most popular forms of snack food, with diversification across different segments of both convenience and health foods. Typical ingredients in a bar are cereal grain, dehydrated fruits or vegetables, seeds, chocolate and dairy. The introduction of the cold chain has allowed for similar foods to emerge in the frozen food segment, such as ice cream bars.

=== Bacteria === Many common culturable laboratory strains are deep-frozen to preserve genetically and phenotypically stable, long-term stocks. Sub-culturing and prolonged refrigerated samples may lead to loss of plasmid(s) or mutations. Common final glycerol percentages are 15, 20, and 25. From a fresh culture plate, one single colony of interest is chosen and liquid culture is made. From the liquid culture, the medium is directly mixed with an equal amount of glycerol; the colony should be checked for any defects like mutations. All antibiotics should be washed from the culture before long-term storage. Methods vary, but mixing can be done gently by inversion or rapidly by vortex and cooling can vary by either placing the cryotube directly at −50 to −95 °C, shock-freezing in liquid nitrogen or gradually cooling and then storing at −80 °C or cooler (liquid nitrogen or liquid nitrogen vapor). Recovery of bacteria can also vary, namely, if beads are stored within the tube then the few beads can be used to plate or the frozen stock can be scraped with a loop and then plated, however, since only little stock is needed the entire tube should never be completely thawed and repeated freeze-thaw should be avoided. 100% recovery is not feasible regardless of methodology.

In 1852, the British signed the Sand River Convention with the Boers, banning the sale of guns to Africans, while continuing to trade between themselves under the terms of the 1854 Bloemfontein Convention. The Boer Orange Free State was able to procure modern breech-loading rifles and a small amount of artillery. The Basuto were forced to rely on smuggled and locally-produced gunpowder, which was of inferior quality. In 1858, hostilities broke out between the Basuto and the Orange Free State. Inferior in both marksmanship and materiel, the Basuto suffered a series of defeats in wars that lasted until 1868. In 1866, the two sides signed the Treaty of Thaba Bosiu, whereby Moshoeshoe ceded most of his kingdom's arable land to the Boers. Hostilities resumed soon afterwards, and the Boers began employing a scorched earth policy, leading to starvation among the Basuto. The Basuto appealed to British High Commissioner for Southern Africa Sir Philip Wodehouse and the Colony of Natal for protection. Although, initially reluctant to intervene, on 12 March 1868 Wodehouse proclaimed Basutoland to be a royal dominion. The Basuto, who became part of the British Empire out of necessity, viewed any kind of colonial administration as "a snake in the house". The British saw it as their responsibility to westernize their new subjects. Wodehouse therefore supported a gradual introduction of colonial laws, so as not to provoke backlash from the Basuto. Basutoland's legal status remained unclear, with the Colonial Office at various times calling it a crown colony and a protectorate.

Sources: en.wikipedia.org

Frequently asked questions

What is the amino acid sequence of Semax?

The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.

How does Semax relate to ACTH?

Semax is a synthetic analog of the ACTH(4-10) fragment rather than a copy of the full hormone. Truncation plus the added tail removes the steroidogenic portion of ACTH. That distinction explains why it is studied for nervous-system effects instead of adrenal stimulation.

Is Semax an approved medicine?

It is registered as a prescription product in Russia and has been used there clinically, chiefly by the intranasal route. No approval exists in the United States or the European Union. Availability elsewhere typically falls under research-chemical distribution, with varying purity documentation.

Is semax an approved medicine?

It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.

Network